Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Tuesday October 27, 2009

DrStockPick.com Stock Report!

TAXS, SCHW, PSFT, DISH, PWRM, MMM, CSRH, WFC, CVAT, JPM, AQNM

**************************************************************

TAXS, TaxMasters Inc., TAXS.OB

TAXS‘ commitment to helping taxpayers in the United States regain compliance with The Internal Revenue Service IRS.

TAXS finalized plans this week to take advantage of the expected surge in sales that begins for the IRS tax relief industry in October and builds through April of the following year. TAXS reported sales for the first six months in 2009 of $18,758,000, an increase of $12,348,000 or 193 percent, over 2008 sales for the same period of $6,410,000. TAXS used this growth

...

MARKET COMMENT April 28, 2009 I wish my Money & Banking class in college was this easy—hell, even gym was hard by comparison to current bank stress tests. Basically it’s an open book test allowing banks to set their own evaluations on some toxic waste and hope investors take it all in stride. The false and misleading statements from CEOs like BAC CEO Ken Lewis are, in ordinary times, shocking. These days it passes for business as usual. “We don’t need any capital….we’re sound...we can return TARP money today…and so forth.” So, BAC and C do in fact need more capital. Who knew!?! Today markets were pulled lower by iffy stress test results and pushed higher by better than expected (there’s that bullish slang again) consumer confidence numbers. Volume remains light and one would imagine more action will result ...

Advanced Life Sciences, Inc. (NASDAQ:ADLS), an Illinois based biopharmaceutical company, today announced submission of a new drug application (NDA) for its lead product, cethromycin, a unique once-a-day antibiotic for respiratory tract infections. The NDA submission is for cethromycin in mild-to-moderate community-acquired pneumonia (CAP). Community-acquired pneumonia is the sixth most common cause of death in the U.S., affecting 5.6 million Americans annually. The company is focusing its resources on the development and commercialization of cethromycin for use in respiratory tract infections such as community-acquired pneumonia, bronchitis, and sinusitis.

Penicillins and macrolides are currently the most common treatment for CAP, but increasing resistance has driven the need for new antibiotics. CEO Michael Flavin, Ph.D., said, “We look forward to advancing the cethromycin NDA through the FDA review process.” The NDA submission is based on a full clinical development and manufacturing program for cethromycin. More than 5,000 patients have been treated with cethromycin in

...

Advanced Life Sciences, Inc. (NASDAQ:ADLS), an Illinois based biopharmaceutical company, today announced submission of a new drug application (NDA) for its lead product, cethromycin, a unique once-a-day antibiotic for respiratory tract infections. The NDA submission is for cethromycin in mild-to-moderate community-acquired pneumonia (CAP). Community-acquired pneumonia is the sixth most common cause of death in the U.S., affecting 5.6 million Americans annually. The company is focusing its resources on the development and commercialization of cethromycin for use in respiratory tract infections such as community-acquired pneumonia, bronchitis, and sinusitis.

Penicillins and macrolides are currently the most common treatment for CAP, but increasing resistance has driven the need for new antibiotics. CEO Michael Flavin, Ph.D., said, “We look forward to advancing the cethromycin NDA through the FDA review process.” The NDA submission is based on a full clinical development and manufacturing program for cethromycin. More than 5,000 patients have been treated with cethromycin in

...

Advanced Life Sciences, Inc. (NASDAQ:ADLS), an Illinois based biopharmaceutical company, today announced submission of a new drug application (NDA) for its lead product, cethromycin, a unique once-a-day antibiotic for respiratory tract infections. The NDA submission is for cethromycin in mild-to-moderate community-acquired pneumonia (CAP). Community-acquired pneumonia is the sixth most common cause of death in the U.S., affecting 5.6 million Americans annually. The company is focusing its resources on the development and commercialization of cethromycin for use in respiratory tract infections such as community-acquired pneumonia, bronchitis, and sinusitis.

Penicillins and macrolides are currently the most common treatment for CAP, but increasing resistance has driven the need for new antibiotics. CEO Michael Flavin, Ph.D., said, “We look forward to advancing the cethromycin NDA through the FDA review process.” The NDA submission is based on a full clinical development and manufacturing program for cethromycin. More than 5,000 patients have been treated with cethromycin in

...